Purchase disclosed
Karen Firestone
Director
Common Stock
- Reported value
- $51.34K
- Reported price
- $13.51 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
Amylyx Pharmaceuticals, Inc.
Last 30 daysNo qualifying insider buying. Sales: $3.78M by 6 insiders.
Director
Common Stock
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Director | Common StockPurchase | 3,800$13.51 / share | $51.34K | May 21Filed May 26 · 5d later | SEC filing |
$12,834 of common-equity purchase value after transaction-age decay across 180 days.
1 distinct reporting-owner group(s). Joint rows count once; identity is not proof of discretion.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
This reflects the filings imported so far, not a complete trading history.